S. Di Candia
Vita-Salute San Raffaele University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by S. Di Candia.
Nutrition Metabolism and Cardiovascular Diseases | 2010
Paolo Brambilla; Antonino Crinò; Giorgio Bedogni; L. Bosio; Marco Cappa; Andrea Corrias; Maurizio Delvecchio; S. Di Candia; Luigi Gargantini; E. Grechi; Lorenzo Iughetti; Alessandro Mussa; Letizia Ragusa; Michele Sacco; Alessandro Salvatoni; Giuseppe Chiumello; Graziano Grugni
BACKGROUND AND AIMS Prader-Willi syndrome (PWS), the most frequent syndromic obesity, is associated with elevated morbidity and mortality in pediatric and adult ages. In PWS, the presence of metabolic syndrome (MS) has not yet been established. The aim of the study was to estimate the frequency of MS and its components in pediatric subjects according to obesity status. METHODS AND RESULTS A cross-sectional study was performed in 109 PWS children aged 2-18 years (50 obese and 59 non-obese) and in 96 simple obese controls matched for age, gender, and also for BMI with obese PWS. Obesity was defined when SDS-BMI was >2. Non-obese PWS showed significantly lower frequency of hypertension (12%) than obese PWS (32%) and obese controls (35%)(p=0.003). The same was observed for low HDL-cholesterol (3% vs 18% and 24%, p=0.001) and high triglycerides (7% vs 23% and 16%, p=0.026). Frequency of altered glucose metabolism was not different among groups (2% vs 10% and 5%), but type 2 diabetes (four cases) was present only in obese PWS. Non-obese PWS showed lower insulin and HOMA-index respect to obese PWS and obese controls (p ≤ 0.017). Overall MS frequency in PWS was 7.3%. None of the non-obese PWS showed MS compared with 16% of obese PWS and controls (p<0.001). When obesity was excluded from the analysis, a significantly lower frequency for clustering of ≥ 2 factors was still found in non-obese PWS (p=0.035). CONCLUSION Non-obese PWS showed low frequency of MS and its components, while that observed in obese PWS was very close to those of obese controls, suggesting the crucial role of obesity status. Prevention of obesity onset remains the most important goal of PWS treatment. Early identification of MS could be helpful to improve morbidity and mortality in such patients.
Nutrition Metabolism and Cardiovascular Diseases | 2013
Graziano Grugni; Antonino Crinò; Giorgio Bedogni; Marco Cappa; Alessandro Sartorio; Andrea Corrias; S. Di Candia; Luigi Gargantini; Lorenzo Iughetti; Claudio Pagano; Letizia Ragusa; Alessandro Salvatoni; S. Spera; Roberto Vettor; Giuseppe Chiumello; Paolo Brambilla
BACKGROUND AND AIMS Prader-Willi syndrome (PWS), the most common genetic cause of obesity, is characterized by elevated morbility and mortality in all ages. In this context, non-obese PWS children showed low frequency of metabolic syndrome (MetS), while a comparable prevalence was observed in obese PWS and obese controls. Aim of this study was to estimate the occurrence of MetS and its components in a large group of PWS adults, according to obesity status. METHODS AND RESULTS A cross-sectional study was performed in 108 PWS aged 18.0-43.2 years (87 obese and 21 non-obese) and in 85 controls with nonsyndromic obesity matched for age, gender, and BMI with obese PWS. Non-obese PWS showed lower waist circumference, insulin, HOMA-index, triglycerides, diastolic blood pressure, and higher HDL-C than both obese PWS and obese controls (p < 0.017). Obese PWS showed higher glucose and systolic blood pressure than both non-obese PWS and obese controls (p < 0.017). MetS was found in 1/21 (4.8%) non-obese PWS, 36/87 (41.4%) obese PWS and 39/85 (45.9%) obese controls. Non-obese PWS showed lower frequency for each MetS component as compared with obese PWS and obese controls. PWS patients with deletion of the chromosome 15q11-13 showed a lower risk for low HDL-C (p < 0.01) and a trend towards a lower MetS risk (p < 0.06) compared to subjects without deletion. CONCLUSION Our findings suggest the main role that obesity status plays on the individual metabolic risk clustering in PWS adults. Early identification of MetS could be helpful to improve morbidity and prevent mortality in such patients.
Hormone Research in Paediatrics | 2012
Alessandro Salvatoni; Jenny Berini; Giuseppe Chiumello; Antonino Crinò; S. Di Candia; Luigi Gargantini; Graziano Grugni; Lorenzo Iughetti; Antonella Luce; G. Musolino; P. Sogno Valin; V. Spica Russotto; G. Trifirò
a Paediatric Endocrinology Unit, Insubria University, Varese , b Paediatric Department, Università Vita e Salute, San Raffaele Hospital, Milan , c Unit of Autoimmune Endocrine Diseases, Bambino Gesù Children’s Hospital, Research Institute, Palidoro-Rome , d Department of Paediatrics, Civic Hospital, Treviglio , e Department of Auxology, S. Giuseppe Hospital, Research Institute, Italian Auxological Institute Foundation, Verbania , f Paediatric Clinic, University of Modena e Reggio Emilia, Modena e Reggio Emilia , and g Paediatric Unit, Hospital of Rho, Rho , Italy
Journal of Endocrinological Investigation | 2010
A. M. Ferrara; Giuseppina Rossi; Emilia Zampella; S. Di Candia; V. Pagliara; I. C. Nettore; D. Capalbo; L De Sanctis; M. Baserga; Mariacarolina Salerno; Gianfranco Fenzi; Paolo Emidio Macchia
Context: Congenital hypothyroidism (CH) is a common endocrine disorder with an incidence of 1:3000–4000 newborns. In 80–85% of cases, CH is caused by defects in thyroid organogenesis, resulting in absent, ectopically located, and/or severely reduced gland, all conditions indicated as “thyroid dysgenesis” (TD). A higher prevalence of congenital heart diseases has been documented in children with CH compared to the general population. This association suggests a possible pathogenic role of genes involved in both heart and thyroid development. Among these, it can be included Isl1, a transcription factor containing a LIM homeodomain that is expressed in both thyroid and heart during morphogenesis. Objective: In the present study, we investigate the role of ISL1 in the pathogenesis of TD. Settings and patients: By single stranded conformational polymorphism, we screened for mutations the entire ISL1 coding sequence in 96 patients with TD and in 96 normal controls. Results: No mutations have been found in patients and controls. Conclusion: Our data indicate that, despite the relevant role of ISL1 in thyroid and heart morphogenesis, mutations in its coding region are not associated with TD in our group of patients.
Nutrition Metabolism and Cardiovascular Diseases | 2016
Danilo Fintini; Graziano Grugni; Sarah Bocchini; C. Brufani; S. Di Candia; Andrea Corrias; Maurizio Delvecchio; Alessandro Salvatoni; Letizia Ragusa; N. Greggio; Adriana Franzese; Emanuela Scarano; G. Trifirò; Laura Mazzanti; Giuseppe Chiumello; Marco Cappa; Antonino Crinò
Hormone Research in Paediatrics | 2012
Alessandro Salvatoni; Jenny Berini; Giuseppe Chiumello; A. Crin; S. Di Candia; Luigi Gargantini; Graziano Grugni; Lorenzo Iughetti; Antonella Luce; G. Musolino; P. Sogno Valin; V. Spica Russotto; G. Trifir
Giornale Italiano di Diabetologia e Metabolismo | 2011
C. Ingegnosi; M. Crapanzano; S. Di Candia; P. Sogno-Valin; Maria Carla Proverbio; Cristina Battaglia; Stefano Mora; V. Guardabasso; S. Bianca; Alessandro Salvatoni; Manuela Caruso-Nicoletti
Congresso Nazionale SIEDP | 2009
P. Sogno Valin; M. Bove; S. Di Candia; Stefano Mora; Maria Carla Proverbio; Alessandra Gessi; A. Gabrieli; Cristina Battaglia; M. Caruso; Alessandro Salvatoni; Giuseppe Chiumello
SIB LLP | 2008
Alessandra Gessi; Maria Carla Proverbio; Eleonora Mangano; Roberta Spinelli; M. Bove; P. Sogno Valin; S. Di Candia; Stefano Mora; L. Bosio; M. Caruso; Alessandro Salvatoni; Giuseppe Chiumello; Cristina Battaglia
European Human Genetics Conference 2008 | 2008
Alessandra Gessi; Maria Carla Proverbio; Eleonora Mangano; Roberta Spinelli; M. Bove; P. Sogno Valin; S. Di Candia; Stefano Mora; L. Bosio; M. Caruso; Alessandro Salvatoni; Giuseppe Chiumello; Cristina Battaglia